Carbetocin at Elective Cesarean Delivery

Study Overview
=================
Brief Summary
-----------------
Post-partum hemorrhage (PPH) is a major cause of maternal death worldwide. Oxytocin is the most commonly uterotonic drug used to prevent and treat PPH in North America, however, there are some limitations to its use. Oxytocin has a very short duration of action, which requires a continuous infusion to achieve sustained uterotonic activity. The Society of Obstetricians and Gynecologists of Canada (SOGC) has recently recommended a single 100mcg dose of carbetocin at elective Cesarean delivery to promote uterine contraction and prevent post partum hemorrhage (PPH), in lieu of the more traditional oxytocin regimens. Carbetocin lasts 4 to 7 times longer than oxytocin, with a similar side effect profile and apparent greater efficacy rate. However, a dose response to determine the minimum effective dose of carbetocin has not yet been published. We hypothesize that a dose-response study will establish the minimum dose of carbetocin required to produce appropriate contractility in 95% of the women (ED95) undergoing elective cesarean delivery.

Detailed Description
-----------------
The Society of Obstetricians and Gynecologists of Canada (SOGC)recently recommended a 100mcg intravenous bolus dose of carbetocin following Cesarean delivery. However, a dose response study to determine the minimum effective dose of carbetocin has not yet been published. Studies thus far show that carbetocin may be just as effective as oxytocin in promoting uterine contraction, with a similar side effects profile. In addition, patients receiving carbetocin may experience less blood loss, and require less additional uterotonics when compared with oxytocin. The results of this study will define the minimum required dose of carbetocin for uterine contraction, thus minimizing unnecessary side effects, improving quality and safety of patient care. It may also contribute in establishing carbetocin as a substitute to oxytocin for elective cesarean section at our institution as well as others.

Official Title
-----------------
Carbetocin at Elective Cesarean Delivery: A Dose Finding Study

Conditions
-----------------
Postpartum Hemorrhage

Intervention / Treatment
-----------------
* Drug: Carbetocin
* Drug: Carbetocin
* Drug: Carbetocin
* Drug: Carbetocin
* Drug: Carbetocin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients planned for elective cesarean delivery under spinal anesthesia; All patients who gave written informed consent to participate in this study. Exclusion Criteria: All patients who refuse to give written informed consent. All patients who claim allergy or hypersensitivity to carbetocin or oxytocin. All patients with conditions that predispose to uterine atony and postpartum hemorrhage such as placenta previa, multiple gestation, preeclampsia, eclampsia, macrosomia, polyhydramnios, uterine fibroids, previous history of uterine atony and postpartum bleeding, or bleeding diathesis. All patients with hepatic, renal, and vascular disease, All patients requiring general anesthesia prior to the administration of the study drug.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Carbetocin 80mcg<br> | Drug: Carbetocin<br>* 80mcg carbetocin, IV, over 1 minute following delivery of the fetal head.<br>* Other names: Duratocin;|
| Active Comparator: Carbetocin 90mcg<br> | Drug: Carbetocin<br>* 90mcg carbetocin, IV, over 1 minute following delivery of the fetal head.<br>* Other names: Duratocin;|
| Active Comparator: Carbetocin 100mcg<br> | Drug: Carbetocin<br>* 100mcg carbetocin, IV, over 1 minute following delivery of the fetal head.<br>* Other names: Duratocin;|
| Active Comparator: Carbetocin 110mcg<br> | Drug: Carbetocin<br>* 110mcg carbetocin, IV, over 1 minute following delivery of the fetal head.<br>* Other names: Duratocin;|
| Active Comparator: Carbetocin 120mcg<br> | Drug: Carbetocin<br>* 120mcg carbetocin, IV, over 1 minute following delivery of the fetal head.<br>* Other names: Duratocin;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Uterine tone. | The obstetrician will assess uterine tone by palpation. Uterine tone will be rated as satisfactory (firm) or unsatisfactory (boggy). | 2 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Uterine tone | Uterine tone will be assessed by palpation 2 hours post-delivery by the nurse/obstetrician in the recovery room. | 2 hours | 
| Blood loss | Blood loss will be calculated through the difference in hematocrit values assessed prior to and at the end of 48 hours after the cesarean section. | 48 hours | 
| Side effects | Any of the following will be noted up to 2 hours post delivery: systolic blood pressure < 80% of pre-delivery values, tachycardia > 30% pre-delivery levels, bradycardia < 30% pre-delivery levels, other dysrhythmias, nausea, vomiting, chest pain, shortness of breath, headache, flushing, others | 2 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pregnancy, postpartum hemorrhage, Cesarean delivery, carbetocin